Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1792581/000110465923034000/tm239172d2_8k.htm
March 2023
March 2023
February 2023
January 2023
December 2022
December 2022
December 2022
December 2022
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1792581/000110465923034000/tm239172d2_8k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Kiromic Biopharma, Inc..
Kiromic Biopharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 8-K Corporate News
Ticker: KRBPEvents:
CIK: 1792581
Form Type: 8-K Corporate News
Accession Number: 0001104659-23-034000
Submitted to the SEC: Fri Mar 17 2023 5:15:07 PM EST
Accepted by the SEC: Fri Mar 17 2023
Period: Tuesday, March 14, 2023
Industry: Biological Products No Disgnostic Substances